Equillium COVID-19 clinical trial shows "significantly reduced mortality"

Today the company Equillium reported that clinical trials of their drug itoizamub “significantly reduced mortality” in patients with COVID-19. Equillium is a clinical-stage biotechnology company whose focus is largely COVID-19-related – like many companies of this sort at the moment. They reported today that a Biocon, India clinical trial with itolizumab “significantly reduced mortality in patients hospitalized with COVID-19.” As …